Skip to content
10-K

Annual Report

Aquestive Therapeutics, Inc. AQST

0001398733-26-000018

← back to feed
Filed
Mar 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 122.05M sh
Shares Diluted FY 2025 · Dec 31, 2025 106.93M sh
Shares Diluted FY 2025 · Dec 31, 2024 86.73M sh
Capex FY 2025 · Dec 31, 2025 $562K
Capex FY 2025 · Dec 31, 2024 $159K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$52.43M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$35.76M
Long Term Debt FY 2025 · Dec 31, 2025 $45M
Stockholders Equity FY 2025 · Dec 31, 2025 −$33.66M
Stockholders Equity FY 2025 · Dec 31, 2024 −$60.16M
Stockholders Equity FY 2025 · Dec 31, 2023 −$106.49M
Current Liabilities FY 2025 · Dec 31, 2025 $47.61M
Current Liabilities FY 2025 · Dec 31, 2024 $18.87M
Total Liabilities FY 2025 · Dec 31, 2025 $194.09M
Total Liabilities FY 2025 · Dec 31, 2024 $161.58M
Current Assets FY 2025 · Dec 31, 2025 $149.27M
Current Assets FY 2025 · Dec 31, 2024 $88.22M
Total Assets FY 2025 · Dec 31, 2025 $160.43M
Total Assets FY 2025 · Dec 31, 2024 $101.42M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.78
Eps Diluted FY 2025 · Dec 31, 2024 −$0.51
Eps Basic FY 2025 · Dec 31, 2025 −$0.78
Eps Basic FY 2025 · Dec 31, 2024 −$0.51
Sga Expense FY 2025 · Dec 31, 2025 $79.85M
Sga Expense FY 2025 · Dec 31, 2024 $50.18M
Rd Expense FY 2025 · Dec 31, 2025 $17.19M
Rd Expense FY 2025 · Dec 31, 2024 $20.28M
Net Income FY 2025 · Dec 31, 2025 −$83.78M
Net Income FY 2025 · Dec 31, 2024 −$44.14M
Operating Income FY 2025 · Dec 31, 2025 −$71.05M
Operating Income FY 2025 · Dec 31, 2024 −$30.77M
Cost Of Revenue FY 2025 · Dec 31, 2025 $18.56M
Cost Of Revenue FY 2025 · Dec 31, 2024 $17.87M
Revenue FY 2025 · Dec 31, 2025 $44.55M
Revenue FY 2025 · Dec 31, 2024 $57.56M